Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Researchers at St. Jude Children's Research Hospital have identified a gene signature in neuroblastoma — the most common solid tumor outside the brain in children — that marks the cancer cells most linked to treatment resistance and poor prognosis. Using cutting-edge tools like single-cell RNA sequencing and spatial omics across 54 tumors from 50 patients, the team built one of the most comprehensive neuroblastoma cell datasets ever, and created new lab models to help drive future research.
Researchers at St. Jude Children's Research Hospital have made a major breakthrough in understanding why some children with neuroblastoma fare far worse than others. Their study, published in Cancer Cell, identifies a gene expression signature that precisely marks malignant mesenchymal cells — the tumor cell population most associated with treatment resistance and poor outcomes — solving a long-standing challenge of distinguishing these dangerous cells from healthy ones in patient tumors.
The team analyzed 54 tumors from 50 patients using an impressive array of technologies, including single-cell RNA sequencing, spatial omics, spatial transcriptomics, and electron microscopy. By growing patient tumor cells in mice (xenografts), they were able to isolate a clear molecular profile of the malignant cells. Crucially, the new gene signature outperformed older methods derived from decades-old cell lines in predicting patient outcomes.
Key Takeaways:
Why it matters: This research gives scientists a validated roadmap and a toolkit to study high-risk neuroblastoma more effectively, potentially accelerating the development of targeted therapies for children with the hardest-to-treat cases.
